Ezetimibe (EZ)/Atorvastatin (Ator) (MK-0653C) vs. Ator in Chinese Hypercholesterolemic Participants (MK-0653C-439)
Status:
Completed
Trial end date:
2021-04-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the EZ/Ator fixed-dose combination (FDC) tablet (MK-0653C) as second
line Low-Density Lipoprotein - Cholesterol (LDL-C) treatment in Chinese participants. The
primary hypothesis is that MK-0653C 10/10 mg is superior to atorvastatin 20 mg in percent
change from baseline in LDL-C to 12 weeks after treatment.